Literature DB >> 11867077

Autosomal dominant palatal myoclonus and spinal cord atrophy.

Yuji Okamoto1, Hideo Mitsuyama, Manabu Jonosono, Keiko Hirata, Kimiyoshi Arimura, Mitsuhiro Osame, Masanori Nakagawa.   

Abstract

We report a new family with palatal myoclonus, pyramidal tract signs, cerebellar signs, marked atrophy of the medulla oblongata and spinal cord, and autosomal dominant inheritance. These findings were almost identical with those in patients previously reported to have histopathologically confirmed adult-onset Alexander disease. Recently, heterozygous point mutations in the coding region of glial fibrillary acidic protein (GFAP) in patients with an infantile form of Alexander disease have been reported. We found a new heterozygous amino acid substitution, Val87Gly in exon 1 of GFAP, in the affected individuals in this family but not in 100 spinocerebellar ataxia (SCA) patients and 100 controls. Therefore, this family might have new clinical entities related to adult-onset Alexander disease and GFAP mutation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867077     DOI: 10.1016/s0022-510x(01)00687-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  17 in total

Review 1.  GFAP and its role in Alexander disease.

Authors:  Roy A Quinlan; Michael Brenner; James E Goldman; Albee Messing
Journal:  Exp Cell Res       Date:  2007-04-06       Impact factor: 3.905

2.  Identification of a novel nonsense mutation in the rod domain of GFAP that is associated with Alexander disease.

Authors:  Tai-Seung Nam; Jin Hee Kim; Chi-Hsuan Chang; Woong Yoon; Yoon Seok Jung; Sa-Yoon Kang; Boo Ahn Shin; Ming-Der Perng; Seok-Yong Choi; Myeong-Kyu Kim
Journal:  Eur J Hum Genet       Date:  2014-04-23       Impact factor: 4.246

3.  Familial Adult-onset Alexander Disease: Clinical and Neuroradiological Findings of Three Cases.

Authors:  Ayşe Deniz Elmali; Ümran Çetinçelik; Civan Işlak; Nurten Uzun Adatepe; Feray Karaali Savrun; Cengiz Yalçinkaya
Journal:  Noro Psikiyatr Ars       Date:  2016-06-01       Impact factor: 1.339

4.  CT and MR imaging of neuroaxonal leukodystrophy presenting as early-onset frontal dementia.

Authors:  M Mascalchi; C Gavazzi; M Morbin; G Giaccone; G Arnetoli; R Zappoli; O Bugiani
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

5.  Late-onset Alexander disease with a V87L mutation in glial fibrillary acidic protein (GFAP) and calcifying lesions in the sub-cortex and cortex.

Authors:  Hidekazu Suzuki; Tomokatsu Yoshida; Mari Kitada; Juri Ichihashi; Hiroshi Sasayama; Yoshiro Nishikawa; Yoshiyuki Mistui; Masanori Nakagawa; Susumu Kusunoki
Journal:  J Neurol       Date:  2011-08-07       Impact factor: 4.849

6.  Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis.

Authors:  Tomokatsu Yoshida; Masayuki Sasaki; Mari Yoshida; Michito Namekawa; Yuji Okamoto; Seiichi Tsujino; Hiroshi Sasayama; Ikuko Mizuta; Masanori Nakagawa
Journal:  J Neurol       Date:  2011-05-01       Impact factor: 4.849

7.  Can MR imaging diagnose adult-onset Alexander disease?

Authors:  L Farina; D Pareyson; L Minati; I Ceccherini; L Chiapparini; S Romano; P Gambaro; R Fancellu; M Savoiardo
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-03       Impact factor: 3.825

Review 8.  Adult-onset Alexander disease with typical "tadpole" brainstem atrophy and unusual bilateral basal ganglia involvement: a case report and review of the literature.

Authors:  Michito Namekawa; Yoshihisa Takiyama; Junko Honda; Haruo Shimazaki; Kumi Sakoe; Imaharu Nakano
Journal:  BMC Neurol       Date:  2010-04-01       Impact factor: 2.474

9.  Alexander disease: a leukodystrophy caused by a mutation in GFAP.

Authors:  Anne B Johnson
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

10.  Adult-onset Alexander disease : report on a family.

Authors:  Pietro Balbi; Marco Seri; Isabella Ceccherini; Carla Uggetti; Roberto Casale; Cira Fundarò; Francesco Caroli; Lucio Santoro
Journal:  J Neurol       Date:  2007-11-21       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.